

Table of contents

List of Tables	i-iii
List of Figures	iv-viii
List of Abbreviations	ix-x
List of Appendices	xi-xiv
Appendix A: List of Publications	xi
Appendix B: List of Seminars, Webinars and Symposiums Presented	xiv
Chapter I: Introduction	1-30
1.1. Revolutionizing drug discovery: The power of computer-aided drug design	3
1.2. Evolution and significance of CADD	4
1.3. Principles and techniques of CADD	5
1.4. Aurora kinase	5
1.4.1. Types of Aurora kinase	5
1.4.2. Function of Aurora kinase	5
1.5. Hepatitis C virus.....	6
1.5.1. Discovery of the hepatitis C virus.....	6
1.5.2. Molecular biology of the hepatitis C virus.....	7
1.5.2.1. NS3/4A protease.....	7
1.5.3. Developed HCV therapeutics: Success and failure.....	8
1.6. Drug repurposing	8
1.6.1. Significance of drug repurposing	9
1.7. COVID-19.....	9
1.7.1. Drug targets of COVID-19	10
1.7.2. Strategies in drug repurposing for COVID-19.....	10
1.7.3. Drugs repurposed against SARS-CoV-2 drug target	11
1.7.3.1. Chloroquine and hydroxychloroquine	11
1.7.3.2. Baricitinib.....	12
1.7.3.3. Remdesivir.....	12
1.8. Monkeypox virus	12
1.8.1. Drugs repurposed against monkeypox virus target.....	13
1.9. Human adenovirus	13
1.9.1. Pediatric Adenovirus or HADV infections in children	13
1.9.2. Adenovirus characteristic.....	14
1.9.3. HADV transmission, incubation, and viral shedding.....	15
1.9.4. Clinical features of HADV infection	15
1.9.5. Treatment of HADV infection	16
1.9.5.1. General treatment	16
1.9.5.2. Antiviral drugs.....	16
1.10. Quantitative structure-activity relationship (QSAR)	16
1.10.1. Brief historical background of QSAR.....	17
1.10.2. Objective of QSAR analysis	19
1.10.3. Classification of QSAR.....	20
1.10.4. QSAR and the OECD guidelines	21
1.10.5. Applications of QSAR	24
1.11. Histone lysine methyl transferase.....	24

1.11.1. Biological function of HKMT in cancers	24
1.11.1.1. EZH2 in cancer	25
1.11.2. Drugs targeting HKMT	25
1.11.3. Targeting EZH2 in cancer	26
1.12. Ghrelin O-acyltransferase	27
1.12.1. Small molecule GOAT inhibitors	28
Chapter II: Methodology	31-58
2.1. Molecular docking	33
2.1.1. The theory of docking	33
2.1.2. Practical aspects in molecular docking	37
2.1.2.1. Protein preparation	37
2.1.2.2. Ligand preparation	38
2.2. Molecular dynamics simulation	38
2.2.1. Work-flow for molecular dynamics simulation	39
2.2.2. Important steps in molecular dynamics simulation	41
2.2.2.1. Energy minimization	41
2.2.2.2. Explicit and implicit solvation	41
2.2.2.3. Periodic boundary conditions	41
2.2.2.4. Computation of long-ranged coulomb interactions	41
2.2.2.5. RMSD, RMSF and radius of gyration	42
2.3. Free energy calculation using MM-PBSA	42
2.3.1. Theory and methods	42
2.4. Quantitative structure-activity relationship (QSAR)	43
2.4.1. Workflow of the QSAR approach	44
2.4.2. Descriptor calculation	45
2.4.3. Preparation, and setup of the input dataset	46
2.4.4. Modeling method in QSAR based on selected descriptors	46
2.4.4.1. Multiple linear regression (MLR)	46
2.4.5. Model exploration, validation, and selection	47
2.4.5.1. View and select models	47
2.4.5.2. Model validation	48
2.4.5.3. Fitting, internal and external validation parameters	49
2.5. Density functional theory (DFT)	52
2.5.1. Hybrid functional	53
2.5.2. Basis set	54
2.5.2.1. Split valence basis set	54
2.5.2.2. Polarized basis set	54
2.5.2.3. Diffusion function	54
2.5.3. Other quantum chemical descriptors	55
2.5.4. Molecular orbital energies	56
2.5.5. Molecular electrostatic potential	57
Chapter IIIA: Screening of drug efficacy of rosmarinic acid derivatives as aurora kinase inhibitors by computer aided drug design method	59-84
3.1.1. Introduction	61
3.1.2. Materials and methods	62
3.1.3. Results and discussion	68
3.1.4. Conclusion	84

Chapter IIIB: Virtual screening of telaprevir and danoprevir derivatives for hepatitis C virus NS3/4A protease inhibitors.....	85-108
3.2.1. Introduction	87
3.2.2. Materials and methods.....	89
3.2.3. Results and discussion.....	96
3.2.4. Conclusion.....	108
Chapter IVA: Preliminary identification of hamamelitannin and rosmarinic acid as COVID-19 inhibitors based on molecular docking	109-120
4.1.1. Introduction	111
4.1.2. Materials and methods.....	113
4.1.3. Results and discussion.....	114
4.1.4. Conclusion.....	119
Chapter IVB: Molecular docking, ADME and toxicity study of some chemical and natural plant based drugs against COVID-19 main protease	121-142
4.2.1. Introduction	123
4.2.2. Materials and methods.....	124
4.2.3. Results and discussion.....	126
4.2.4. Conclusion.....	141
Chapter IVC: Repurposing of existing pharmaceutical drugs against monkeypox virus: An <i>in silico</i> study.....	143-162
4.3.1. Introduction	145
4.3.2. Materials and methods.....	146
4.3.3. Results and discussion.....	149
4.3.4. Conclusion.....	162
Chapter IVD: Computational insights into pediatric adenovirus inhibitors: <i>In silico</i> strategies for drug repurposing	163-188
4.4.1. Introduction	165
4.4.2. Materials and methods.....	167
4.4.3. Results and discussion.....	169
4.4.4. Conclusion.....	187
Chapter VA: QSAR study of benzofuran and indole derivatives to predict new compounds as histone lysine methyl transferase inhibitors	189-216
5.1.1. Introduction	191
5.1.2. Materials and methods.....	193
5.1.3. Results and discussion.....	200
5.1.4. Conclusion.....	215
Chapter VB: Discovery of new oxadiazolo pyridine derivatives as potent ghrelin O-acyltransferase inhibitors using molecular modeling techniques	217-244
5.2.1. Introduction	219
5.2.2. Materials and methods.....	220
5.2.3. Results and discussion.....	227
5.2.4. Conclusion.....	242
Scope for Future Study.....	245
Concluding Remarks	247
References.....	253
Index.....	287
Reprints	289